← boardnext 2027-12next 2029-02
ALLO
Allogene Therapeuticsdistress 5/10 · elevated risk$1.80-3%today-41% from 52w high
Oncology 2
Lead: Large B-cell lymphoma · target BCMA · est. market ~$18B (approx, global)
Revenue
pre-revenue
Liquidity
$314M
Runway
2.9 yrs
Shares 1y
+56%
Price & events
+4.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
+0.8%
1W
-12.8%
1M
-23.2%
3M
+4.9%
6M
+8.7%
1Y
-41.4%
2Y
-91.8%
5Y
-93.0%
All
Overview
- Market Cap
- $623.00M
- Volume
- 389.20K
- 52 Week Range
- $1.03 – $3.06
- Total Shares
- 345.15M
- Float Shares
- 270.63M
- Short %
- 20.32%
- % Held by Insiders
- 11.04%
- % Held by Institutions
- 53.66%
- RVOL
- 0.04x
- Beta
- 0.46
Pipeline stages · 2 programs
cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ALLO-501A, ALLO-647, Fludarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide | Large B-cell Lymphoma | — | recruiting |
| 2029-02 Estimated 50% readout ~2029-03-18 | Phase 1/2 | ALLO-501A, ALLO-647, Fludarabine | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | — | active not recruiting |
| 2025-10 | Phase 1 | ALLO-316, ALLO-647, Fludarabine | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | 120 | active not recruiting |
| 2025-01-27 | Phase 1 | ALLO-715, ALLO-647, Fludarabine | Relapsed/Refractory Multiple Myeloma | 73 | completed |
Catalyst news & presentations · 7
- mid-2028Guided 55%readoutPhase 2cemacabtagene ansegedleucel · Anticipated primary EFS analysisSEC 8-K
- end of 2027Guided 40%enrollment completesecondaryPhase 2cemacabtagene ansegedleucel · Expected completion of patient enrollmentSEC 8-K
- mid-2027Guided 55%readoutPhase 2cemacabtagene ansegedleucel · Anticipated interim EFS analysisSEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutcemacabtagene ansegedleucel (cema-cel) · Futility analysis comparing MRD conversionSEC 8-K
- 2026-04-13readoutPhase 2cemacabtagene ansegedleucel · Interim futility analysis data readoutSEC 8-K
- 2024-11-11trial discontinuedcema-cel · Discontinued enrollment in Phase 1 cohort for relapsed/refractory CLL due to slow enrollmentSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+399% upside) · 9 analysts
- 2026-04-16HC Wainwright & Co.Buy
- 2026-04-16JP MorganUnderweight → Neutral
- 2026-04-15JefferiesBuy
- 2026-04-14CitizensMarket Outperform
- 2026-04-14Argus ResearchMarket Perform
- 2026-04-14BernsteinMarket Perform
Competitors — BCMA
Recent news
- 2026-07-15Allogene Therapeutics (ALLO) Unveils Promising Phase 1 Study Res - GuruFocus
- 2026-07-15Allogene reports 31% response rate in renal cancer trial - Investing.com
- 2026-07-15Allogene Therapeutics Announces Journal of Clinical - GlobeNewswire
- 2026-07-13Allogene Therapeutics (ALLO) Q3 2024 earnings summary - Quartr
- 2026-07-09Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals
- 2026-07-06Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
- 2026-07-06Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan
- 2026-07-04Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.